Close

UPDATE: H.C. Wainwright Starts Aquestive Therapeutics (AQST) at Buy

April 22, 2019 7:11 AM EDT
Get Alerts AQST Hot Sheet
Price: $1.07 -3.6%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 9 | New: 24
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - April 22, 2019 8:37 AM EDT)

(updated to add analyst comments)

H.C. Wainwright initiates coverage on Aquestive Therapeutics (NASDAQ: AQST) with a Buy rating and a price target of $10.00.

The analyst commented, "Aquestive Therapeutics is an emerging specialty pharma company optimizing the delivery of existing, well-known medications. The company's core technology platform, PharmFilm, is already the basis of several approved products. PharmFilm permits the delivery of hitherto-challenging active pharmaceutical ingredients (APIs) on oral film that dissolves in the mouth—either buccal (inside of the cheek), sub-lingual (under the tongue) or lingual (on the tongue)—to address the issues associated with oral capsules or tablets for patients suffering from dysphagia (difficulty swallowing). Existing products utilizing PharmFilm include Suboxone (a combination of buprenorphine and naloxone) to treat opioid addiction, Zuplenz (ondansetron) for nausea and vomiting, and Sympazan (clobazam), used to treat Lennox-Gastaut Syndrome (LGS), an orphan seizure disorder. Aquestive also has multiple candidates in late-stage development, including Libervant (diazepam buccal film) for treatment of refractory seizures and Exservan (riluzole oral film) for treatment of amyotrophic lateral sclerosis (ALS)—we project the launch of both candidates in 2020. An anti-Parkinson's disease candidate, APL-130277 (sub-lingual apomorphine film), is nearing registration as well—this is partnered with Sunovion, a U.S. subsidiary of the established Japanese firm Dainippon Sumitomo Pharma—and would, if approved, yield low single-digit royalties on net sales to Aquestive, along with up to $45M in milestone payments. We are initiating coverage with a Buy rating and 12-month price target of $10 per share."

For an analyst ratings summary and ratings history on Aquestive Therapeutics click here. For more ratings news on Aquestive Therapeutics click here.

Shares of Aquestive Therapeutics closed at $6.29 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

H.C. Wainwright